Could a Low-Carb diet and exercise help brain cancer patients?
NCT ID NCT06665373
First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This pilot study is testing whether combining a modified Atkins diet (low-carb, high-protein) with a 12-week fitness program can improve quality of life and physical function in 15 people with malignant glioma. Participants will follow the diet and attend two supervised exercise sessions per week plus a home program. The goal is to see if this lifestyle approach is feasible and beneficial for this patient group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Modified Atkins diet and fitness program
- What this could lead to
- If it works, this could point toward a supportive lifestyle approach to help people with malignant glioma feel better and stay more active during their treatment.
- What could go wrong
- This is a very small pilot study with only 15 participants and no control group, so results may not apply widely. The diet and exercise regimen may be hard to follow for some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal fluid DNA test could personalize brain cancer therapy
- Experimental vaccine aims to rally immune system against recurrent brain cancer
- Immunotherapy drug nivolumab tested in young brain cancer patients
- Brain Tumor's hidden electrical signals could reveal its weaknesses
- New hope for aggressive brain tumors? early trial combines two targeted drugs
- Supercharged immune cells take on deadly brain tumors